Keeley-Teton Advisors’s Haemonetics HAE Stock Holding History

Keeley-Teton Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$718K	Buy	11,294 +5,804	+106%	+$395K	0.09%	251
2024 Q4	$429K	Sell	5,490 -870	-14%	-$69.9K	0.05%	304
2024 Q3	$511K	Hold	6,360	–	–	0.06%	300
2024 Q2	$526K	Hold	6,360	–	–	0.07%	275
2024 Q1	$543K	Hold	6,360	–	–	0.07%	270
2023 Q4	$544K	Hold	6,360	–	–	0.07%	269
2023 Q3	$570K	Hold	6,360	–	–	0.08%	251
2023 Q2	$541K	Hold	6,360	–	–	0.07%	269
2023 Q1	$526K	Buy	6,360 +500	+9%	+$40.5K	0.07%	285
2022 Q4	$461K	Buy	5,860 +1,460	+33%	+$117K	0.06%	298
2022 Q3	$326K	Hold	4,400	–	–	0.04%	317
2022 Q2	$287K	Hold	4,400	–	–	0.04%	341
2022 Q1	$278K	Buy	+4,400	New	+$239K	0.03%	361

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Keeley-Teton Advisors's HAE Position: Q1 2025 in Review

Keeley-Teton Advisors increased its Haemonetics (HAE) stake by 106% in Q1 2025, buying an estimated $395K and bringing the position to 11,294 shares worth $718K. The position accounts for 0.09% of the portfolio, ranked #251.

Keeley-Teton Advisors first reported a position in HAE in Q1 2022 and has held it in 13 quarters since. 314 funds tracked by Wall St. Rank hold HAE as of Q1 2025.

Keeley-Teton Advisors held 11,294 shares of Haemonetics worth $718K as of Q1 2025.
Keeley-Teton Advisors bought 5,804 Haemonetics shares in Q1 2025, an estimated $395K.
Haemonetics made up 0.09% of Keeley-Teton Advisors's portfolio in Q1 2025, its #251 holding.
Keeley-Teton Advisors first reported a position in Haemonetics in Q1 2022 and has held it in 13 quarters since.
314 funds tracked by Wall St. Rank held Haemonetics as of Q1 2025.

Based on Keeley-Teton Advisors's 13F filing for Q1 2025, filed 14 May 2025.